APrevent
APrevent's products improve voice and communication, focusing on the development of a long- term implant system and speech conversion platform for patients with glottic insufficiency and dysarthria.
Launch date
Employees
Market cap
-
Enterprise valuation
$24—36m (Dealroom.co estimates May 2024.)
Company register number FN 432512y
Stadt Feldkirch Vorarlberg (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | <1m | <1m | <1m |
| % growth | - | 33 % | 25 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.0m | Seed | |
N/A | - | ||
* | $6.0m | Series D | |
| Total Funding | $12.0m | ||
Related Content
Recent News about APrevent
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.